Observational studyCritical care explorations2025
Urine Olfactomedin 4 Predicts Furosemide Response and Kidney Replacement Therapy in Critically Ill Children.
Observational study in Critical care explorations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesTo test whether urine olfactomedin 4 (uOLFM4) can predict furosemide responsiveness in patients at high risk for acute kidney injury (AKI) early in the PICU course. A secondary outcome was prediction of kidney replacement therapy (KRT) initiation in this cohort.
designProspective observational cohort study.
settingTwo quaternary care PICUs. PATIENTS: Two hundred forty PICU patients with a renal angina index greater than or equal to 8 and a urine sample collected on PICU days 0-1. Fifty-six patients received a furosemide dose on PICU days 1-4 and 44 received KRT.
interventionsNone. MEASUREMENTS AND MAIN
resultsuOLFM4 was measured via enzyme-linked immunosorbent assay. Urine neutrophil gelatinase-associated lipocalin (uNGAL) was measured via particle-enhanced turbidimetric immunoassay by the clinical laboratory. We compared groups using Mann-Whitney U tests or Kruskal-Wallis tests and calculated area under the receiver operating characteristic curve for performance of uOLFM4 and uNGAL to predict furosemide responsiveness on PICU days 1-4 and KRT receipt. Median (interquartile range) uOLFM4 and uNGAL concentrations were higher in patients who were furosemide nonresponsive (uOLFM4 694 ng/mL [214-1478 ng/mL] vs. 139 ng/mL [46-529 ng/mL]; p = 0.0004 and uNGAL 1149 ng/mL [204-2284 ng/mL] vs. 53 ng/mL [50-1533 ng/mL]; p = 0.0076) and higher in patients who received KRT. uOLFM4 and uNGAL had similar moderate discriminatory ability to predict furosemide responsiveness (area under the curve, 0.77 [95% CI, 0.65-0.90]; p = 0.0005 and 0.71 [95% CI, 0.57-0.85]; p = 0.0088, respectively). uOLFM4 of 156 ng/mL had 59% sensitivity, 96% specificity, a positive predictive value of 64%, and negative predictive value (NPV) of 95% to predict furosemide responsiveness.
conclusionsIn critically ill children at high risk for AKI, both uOLFM4 and uNGAL have moderate discriminatory ability to predict furosemide responsiveness and KRT receipt on the first day of PICU stay. The NPV greater than or equal to 95% for uOLFM4 for both outcomes make it a promising candidate for implementation into clinical decision support to facilitate early KRT initiation decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.